InDex Pharmaceuticals is an immunology focused biopharmaceutical company. We have developed two assets from our in-house, proprietary technology platform:
Currently in a Phase III trial in steroid resistant Ulcerative Colitis
A preclinical potential treatment for steroid resistant AsthmaWe are dedicated to discovering and developing treatments exclusively in disease states where there is a high unmet medical need. In the case of Kappaproct, there is today no alternative pharmaceutical treatment, with highly invasive surgery as the only available option for patients. Kappaproct has received an Orphan Drug Designation from the EMA.
We are also dedicated to personalized medicine. In both our programs we are developing companion diagnostics that will allow selection of only those patients who are likely to respond to treatment.
InDex Pharmaceuticals has developed and launched in Sweden the diagnostic test DiBiCol®. DiBiCol allows for the discrimination between Ulcerative Colitis and Crohn's Disease.
It is our conviction that our focus on indications with high unmet medical needs combined with our commitment to personalized medicine will create significant value for all our stakeholders: patients, caregivers, payors and InDex Pharmaceuticals shareholders.
